RxDoctor Payments Data

Sanjay Yadav, MD

Hematology & Oncology · Columbus, OHNPI 1528177714

Payments from drug & device makers

$703in general payments, 2019–2025

Across 27 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$202
  • Merck$125
  • Eisai Inc.$73
  • Novartis$53
  • AstraZeneca$39
  • E.r. Squibb & Sons, L.L.C.$33
  • plus $179 from 8 others

What the payments were for

  • Food & beverage$30543%
  • Education$39857%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$703 in reported general payments places this provider in the 20th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$88,370
Medicare patients
401
Services billed
1,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide27$480,906
PomalystPomalidomide11$251,449
IbrancePalbociclib13$240,697
ImbruvicaIbrutinib15$233,611
VerzenioAbemaciclib15$233,415
LynparzaOlaparib11$212,224
ErleadaApalutamide14$211,355
BrukinsaZanubrutinib13$195,436
LapatinibLapatinib Ditosylate12$81,190
Abiraterone Acetate19$53,482
EliquisApixaban53$53,342
XareltoRivaroxaban19$20,821
Imatinib Mesylate15$4,385
Enoxaparin Sodium14$4,332
Anastrozole143$2,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$24$480,90627 claims
PfizerIbrance, Eliquis$31$294,03966 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$33$251,44911 claims
Lilly USA, LLCVerzenio$202$233,41515 claims
Johnson & JohnsonErleada, Xarelto$17$232,17533 claims
AstraZenecaLynparza$39$212,22411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →